

# Corporate Factsheet

August 2025

## Company Profile

OrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. OrbusNeich is listed on the Main Board of the Hong Kong Stock Exchange under the stock code 6929.

Employees worldwide

 **1,400+**

Leadership

 **20+** Years of experience


Core management team

Innovation

 **250+**

Granted patents & published patent applications globally

Bases

 **2** R&D facilities  
**3** Production centers

Capacity

 **2.1** million balloons and stents

Annual production capacity

Sales network

 **70+**

Countries & regions

## Excellent capabilities in R&D, Operation and Commercialization

### R&D

#### R&D development

- Over 250 granted patents and published patent applications globally
- US clinical trial for Sapphire 3 is progressing on schedule

#### Product approval

- FDA: COREPASS
- CE: JADE PLUS, Teleport Glide
- PMDA: Scoreflex QUAD, Teleport Glide
- NMPA: Guiding catheter

### Operation

#### New facility construction


- Construction of the main structure of our largest R&D and manufacturing facility in Hangzhou was completed in August 2025

#### Third-party collaboration

- Entered into a long-term strategic partnership with SonoScape to distribute IVUS systems on an exclusive basis in 8 direct sales markets and 6 distributor markets in APAC and Europe

### Commercialization

- Sales network covering over 70 countries and regions
- Direct and distributor sales accounted for 58% and 42% of total sales in 1H 2025 respectively
- Held or participated in around 48 seminars, workshops, conferences, discussion panels and Physician Exchange Program globally in 1H 2025



Headquarters  
Hong Kong, China



R&D and Production Center  
Shenzhen, China



EU Regional Headquarters &  
Production Center  
Hoevelaken, the Netherlands




Production Center  
Weil am Rhein, Germany



Advanced Technology  
Laboratory  
Tokyo, Japan

Product portfolio





As of June 30, 2025

|     | Lesion Access  | Lesion Preparation  | Lesion Therapy   | Lesion Optimization                                   |
|-----|--|---|--|---|
| PCI | <div><div>Teleport</div><div>Teleport<sup>XT</sup></div><div>SAPPHIRE<sup>3</sup></div><div>SAPPHIRE<sup>II</sup> PRO</div><div>EZGuide</div><div>Xtenza</div></div> | <div><div>SAPPHIRE<sup>II</sup> PRO</div><div>SAPPHIRE<sup>3</sup></div><div>SAPPHIRE<sup>NC</sup> 24</div><div>scoreflex<sup>TRIO</sup></div><div>scoreflex<sup>NC</sup></div></div> | <div><div>COMBO<sup>+</sup> PLUS</div><div>eucaLimus</div><div>SUPPORT C</div></div> | <div><div>SAPPHIRE<sup>NC</sup> 24</div></div>        |
| PTA | <div><div>Teleport</div><div>Teleport<sup>XT</sup></div><div>SAPPHIRE<sup>II</sup> PRO</div></div>   | <div><div>JADE</div><div>JADE<sup>2</sup></div><div>scoreflex<sup>PTA</sup></div></div>   | <div><div>RESISTANT</div><div>VITUS</div></div>                                      | <div><div>JADE</div><div>JADE<sup>2</sup></div></div> |

Key Financial Figures

Breakdown of revenue for 1H 2025



Corporate Headquarters

Address | Units 303 & 305, 3/F, Building 20E, Hong Kong Science Park, Shatin, N.T. Hong Kong  
Phone | +852 2802 2288      Email | [pr@orbusneich.com](mailto:pr@orbusneich.com)

[www.OrbusNeich.com](http://www.OrbusNeich.com)